Johanna Friedl-Naderer, Chief Commercial Officer at Dyne Therapeutics, Inc. (DYN), sold 228 shares at $18.36 ($4K) on 2026-05-13, disclosed to the SEC on 2026-05-14.
Scheduled sale ($4k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| DYN | SELL | 2026-06-17 | $3K | — | Filing → |
| DYN | SELL | 2026-03-06 | $2K | — | Filing → |
| DYN | SELL | 2025-12-05 | $3K | — | Filing → |